Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 5/20 | 0.67 |
| ▸ | AXL | P30530 | 3/20 | 0.67 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.59 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.54 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.54 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.54 |
| ▸ | FLT3 | P36888 | 3/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.52 |
| ▸ | KDR | P35968 | 3/20 | 0.52 |
| ▸ | JAK2 | O60674 | 2/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.52 |
| ▸ | CDK1 | P06493 | 2/20 | 0.52 |
| ▸ | RET | P07949 | 2/20 | 0.52 |
| ▸ | ROS1 | P08922 | 2/20 | 0.52 |
| ▸ | FER | P16591 | 2/20 | 0.52 |
| ▸ | FLT1 | P17948 | 2/20 | 0.52 |
| ▸ | FLT4 | P35916 | 2/20 | 0.52 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.52 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4786218 | 0.85 | CDK8 (0.54) | CDK8AXLRIPK1FLT3AURKB | |
| SCHEMBL13854142 | 0.83 | CDK8 (0.74) | CDK8AXLRIPK1PIK3CDPIK3CA | |
| SCHEMBL410704 | 0.81 | CDK8 (1.00) | CDK8AXLRIPK1PIK3CDPIK3CA | |
| SCHEMBL13854149 | 0.81 | RIPK1 (0.61) | CDK8AXLRIPK1PIK3CDPIK3CA | |
| SCHEMBL3901006 | 0.80 | NPC1 (0.64) | ABL1NSD2PPARGRIN1L3MBTL1 | |
| SCHEMBL858559 | 0.78 | RIPK1 (0.58) | CDK8AXLRIPK1PIK3CDPIK3CA | |
| SCHEMBL12127570 | 0.77 | BRD4 (0.65) | CDK8AXLRIPK1PIK3CDPIK3CA | |
| SCHEMBL412385 | 0.77 | RIPK1 (0.57) | CDK8AXLRIPK1PIK3CDPIK3CA | |
| SCHEMBL4857195 | 0.77 | CDK8 (0.73) | CDK8AXLRIPK1PIK3CDPIK3CA | |
| SCHEMBL29941056 | 0.77 | CDK8 (0.73) | CDK8AXLRIPK1PIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2016-06-23 | — | — | US | disclosed |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2016-06-23 | — | — | US | disclosed |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20130261117-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2013-10-03 | — | — | US | disclosed |
| US-20130261117-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2013-10-03 | — | — | US | disclosed |
| US-8470818-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470818-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120022098-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2012-01-26 | — | — | US | disclosed |
| US-20120022098-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2012-01-26 | — | — | US | disclosed |
| US-20110059963-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2011-03-10 | — | — | US | disclosed |
| US-20110059963-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2011-03-10 | — | — | US | disclosed |
| US-7863288-B2 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-7863288-B2 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-20100256365-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100256365-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON INC. | 2010-09-30 | — | — | US | disclosed |
| WO-2007002433-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | MAP4K1, MAP4K2, MAP3K1 | CDK8 185/4885AXL 861/4885RIPK1 473/4885 |
| US-20120022098-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CDK8 56/4885AXL 1354/4885RIPK1 507/4885 |
| US-20110059963-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CDK8 56/4885AXL 1354/4885RIPK1 507/4885 |
| US-20130261117-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CDK8 56/4885AXL 1354/4885RIPK1 507/4885 |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CDK8 56/4885AXL 1354/4885RIPK1 507/4885 |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CDK8 56/4885AXL 1354/4885RIPK1 507/4885 |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CDK8 56/4885AXL 1354/4885RIPK1 507/4885 |
| US-20100256365-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CDK8 56/4885AXL 1354/4885RIPK1 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.